Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Context: Abnormalities in calcium metabolism are common in chronic kidney disease (CKD). Diminished urinary calcium excretion may promote vascular calcification and increased urinary calcium excretion may lead to nephrolithiasis and nephrocalcinosis, conditions associated with CKD.
Objective: To study predictors of urinary calcium excretion and its association with adverse clinical outcomes in CKD.
Design, Setting And Patients: This study assessed 3768 nondialysis participants in the Chronic Renal Insufficiency Cohort study from April 2003 to September 2008. Participants were followed up to October 2018.
Exposure: Clinically plausible predictors of urinary calcium excretion and 24-h urinary calcium excretion at baseline.
Main Outcome Measures: Urinary calcium excretion; incident end stage kidney disease (ESKD), CKD progression [50% estimated glomerular filtration rate (eGFR) decline or incident ESKD], all-cause mortality, and atherosclerotic cardiovascular disease events.
Results: eGFR was positive correlated with 24-h urinary calcium excretion. The variables most strongly associated with 24-h urinary calcium excretion in males and females were 24-h urinary sodium (β = 0.19 and 0.28, respectively), serum parathyroid hormone (β = -0.22 and -0.20, respectively), loop diuretics (β = 0.36 and 0.26, respectively), thiazide diuretics (β = -0.49 and -0.53, respectively), and self-identified black race (β = -0.23 and -0.27, respectively). Lower urinary calcium excretion was associated with greater risks of adverse outcomes, but these associations were greatly attenuated or nullified after adjustment for baseline eGFR.
Conclusion: Urinary calcium excretion is markedly lower in individuals with CKD compared to the general population. Determinants of urinary calcium excretion differed between sexes and levels of CKD. Associations between urinary calcium excretion and adverse clinical events were substantially confounded by eGFR.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684460 | PMC |
| http://dx.doi.org/10.1210/clinem/dgab574 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cooling-induced brushite crystallization in urine as a predictive risk marker for calcium kidney stone recurrence.
Urolithiasis
September 2025
Graduate School of Engineering, The University of Osaka, 2-1, Yamadaoka, Suita, 565- 0871, Japan.
Kidney stones have a high recurrence rate-10% within 5 years and 50% within 10. Crystalluria reflects the urinary physicochemical environment and may serve as a recurrence marker, but key crystals like brushite are rarely detected under ambient conditions. This study aimed to identify novel recurrence markers by inducing crystallization through urine cooling and analyzing crystal composition.
View Article and Find Full Text PDF24-h urine test application in patients with kidney stone disease: a population-based study in a primary care setting.
J Nephrol
September 2025
Italian Society of General Medicine (SIMG), COMEGEN Primary Care Physicians Cooperative, Naples, Italy.
Background: Kidney stone formation is driven by an imbalance between lithogenic substances and crystallization inhibitors. Current guidelines recommend a 24-h urine collection in patients with kidney stone disease to assess the risk of stone formation and monitor therapy compliance. However, real-world data on adherence to these guidelines remain limited and outdated.
View Article and Find Full Text PDFA potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use.
Endocrinol Diabetes Metab Case Rep
July 2025
Department of Internal Medicine, Medical City Arlington, Arlington, Texas, USA.
Summary: Hypercalcemia is a prevalent electrolyte disturbance commonly associated with primary hyperparathyroidism, cancer, or medication adverse effects. Thiazide diuretics reduce urinary calcium excretion, increasing calcium reabsorption and hypercalcemia. Tirzepatide, a dual GIP and GLP-1 receptor agonist, is increasingly used for type 2 diabetes and obesity.
View Article and Find Full Text PDFPelvic inflammatory pseudotumor with calcium polystyrene sulfonate crystal deposition in a kidney transplant recipient.
CEN Case Rep
September 2025
Department of Nephrology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, Japan.
A 63-year-old woman underwent living-donor kidney transplantation three years earlier for end-stage renal disease due to diabetic nephropathy, with her younger sister as the donor. She was prescribed calcium polystyrene sulfonate for the management of hyperkalemia, which had been discontinued two years earlier. At this time, she developed recurrent abdominal and urinary symptoms, which were managed empirically with antibiotics.
View Article and Find Full Text PDFElabela increases in patients with primary hyperparathyroidism, especially in the presence of surgery indication.
BMC Endocr Disord
September 2025
Department of Internal Medicine, University of Health Sciences - Adana Health Practice and Research Center, Dr. Mithat Özsan Bulvarı Kışla Mah. 4522 Sok. No: 1, Yüreğir, Adana, Turkey.
Aim: Patients with primary hyperparathyroidism (PHPT) are known to have structural and functional changes in the vascular system. Bioactive peptides associated with the apelinergic system play a role in ischemic heart disease and atherosclerosis. In this study, we aimed to investigate the changes in serum elabela, a novel apelinergic system peptide, and its relationship with aortic intima media (AIM) measurements in patients with newly diagnosed primary hyperparathyroidism.
View Article and Find Full Text PDF